BOSTON SCIENTIFIC SLIPS TO LOSS IN Q2 HURT BY CHARGES ON GUIDANT ACQUISITION

Thursday, Boston Scientific Corp., medical device company, revealed second quarter financial results, reporting a net loss primarily from charges related to the acquisition of Guidant Corp. The company, however, reported revenues exceeding the $2 billion mark and said it was set to achieve annual sales of approximately $9 billion with an EBITDA, prior to special charges and stock compensation expenses, of approximately $2.9 billion. Trading Markets (http://www.tradingmarkets.com/tm.site/news/TOP%20STORY/321677/)